EMA’s safety committee (PRAC) has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group. EMA is reminding healthcare professionals and people receiving the vaccine to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within 2 weeks of vaccination. So far, most of the cases reported have occurred in women under 60 years of age within 2 weeks of vaccination. Based on the currently available evidence, specific risk factors have not been confirmed.
- EMA confirms overall benefit-risk remains positive https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
- A Small Number of People Developed This Rare Blood Disorder After Getting a COVID Vaccine—Here's What to Know. https://www.health.com/condition/infectious-diseases/coronavirus/rare-blood-disorder-covid-vaccine-thrombocytopenia
- Can people with blood infections or disorders get vaccines? https://covidvaccinehub.org/articles/can-people-with-blood-infections-or-disorders-get-vaccines
- Canadian researchers closer to understanding how AZ vaccine recipients develop rare blood clots. https://www.ctvnews.ca/health/coronavirus/canadian-researchers-closer-to-understanding-how-az-vaccine-recipients-develop-rare-blood-clots-1.5500015
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2021